Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
What is the significance of LVSI in determining post-op management for oropharyngeal cancer?
Would you recommend PORT based on LVSI as the sole risk factor (i.e. pT1/T2N0 OP SCCa)?
Answer from: Radiation Oncologist at Academic Institution
It doesn’t change my management.
Sign In
or
Register
to read more
17974
Related Questions
For unresectable-appearing BRAF V600E papillary thyroid cancer involving the trachea and carotid artery, is neoadjuvant targeted therapy a viable path to surgery, or is definitive radiation the better option?
How are you integrating the findings from KEYNOTE-689 into daily practice?
For an upper lip (near midline) Merkel cell carcinoma s/p wide local excision with negative SLNB and no adjuvant RT, with the recurrence to one side of the neck a year later, should the contralateral neck be included in the radiation field?
What is the role of radiation therapy for Kimura's disease of the parotid and neck?
How would you approach a patient treated for a stage I glottic cancer 2 years prior with a biopsy proven recurrence who is declining surgery and any systemic therapy?
What is your recommendation for patients who are on weight loss medications like GLP-1-based therapies while receiving chemoradiation for head and neck cancer?
What is the role for chemo immunotherapy in the up front setting in non-metastatic head & neck cancer outside of clinical trials?
How would you manage the side effects/toxicities (e.g., pain, swelling, erythema) of adjuvant EBRT to the ear for cutaneous SCC?
What alternatives do you recommend for oral dexamethasone solution for HN cancer?
Would you recommend adjuvant radiation for a patient with head/neck merkel cell carcinoma following a pathologic complete response to neoadjuvant immunotherapy?